{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:45:35Z","timestamp":1767901535196,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.nano.2024.102743","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T03:21:19Z","timestamp":1710300079000},"page":"102743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Bioresponsive nanocomplex integrating cancer-associated fibroblast deactivation and immunogenic chemotherapy for rebuilding immune-excluded tumors"],"prefix":"10.1016","volume":"58","author":[{"given":"Lisha","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianggui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopeng","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meirong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2024.102743_bb0005","article-title":"Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment","volume":"14(670):eabo3605","author":"Kirchhammer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.nano.2024.102743_bb0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.nano.2024.102743_bb0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.nano.2024.102743_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.phrs.2017.07.006","article-title":"Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance","volume":"123","author":"Pulluri","year":"2017","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.nano.2024.102743_bb0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","article-title":"Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance","volume":"18","author":"Fiori","year":"2019","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.nano.2024.102743_bb0030","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1002\/anie.202014397","article-title":"Transformable honeycomb-like Nanoassemblies of carbon dots for regulated multisite delivery and enhanced antitumor Chemoimmunotherapy","volume":"60","author":"Hou","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"issue":"12","key":"10.1016\/j.nano.2024.102743_bb0035","doi-asserted-by":"crossref","first-page":"10631","DOI":"10.1021\/acsnano.6b07673","article-title":"Using gold nanoparticles to disrupt the tumor microenvironment: an emerging therapeutic strategy","volume":"10","author":"Melamed","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2024.102743_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119745","article-title":"Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors","volume":"232","author":"Han","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2024.102743_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120481","article-title":"Biomineralization-inspired dasatinib nanodrug with sequential infiltration for effective solid tumor treatment","volume":"267","author":"Liu","year":"2021","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.nano.2024.102743_bb0050","first-page":"6831","article-title":"Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model","volume":"15","author":"Song","year":"2018","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.nano.2024.102743_bb0055","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1038\/s41467-022-33831-7","article-title":"In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses","volume":"13","author":"Guo","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.nano.2024.102743_bb0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s43018-020-0048-0","article-title":"EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer","volume":"1","author":"Gong","year":"2020","journal-title":"Nat Can"},{"issue":"5","key":"10.1016\/j.nano.2024.102743_bb0065","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acsnano.7b01522","article-title":"Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles","volume":"11","author":"Hu","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2024.102743_bb0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.biomaterials.2016.08.041","article-title":"Generation of an in vitro 3D PDAC stroma rich spheroid model","volume":"108","author":"Ware","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2024.102743_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121518","article-title":"The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment","volume":"284","author":"Zhang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2024.102743_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116527","article-title":"Doxorubicin delivered by redox-responsive hyaluronic acid-ibuprofen prodrug micelles for treatment of metastatic breast cancer","volume":"245","author":"Chai","year":"2020","journal-title":"Carbohydr Polym"},{"issue":"1","key":"10.1016\/j.nano.2024.102743_bb0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.nano.2024.102743_bb0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2021.06.030","article-title":"In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles","volume":"336","author":"Wang","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2024.102743_bb0095","doi-asserted-by":"crossref","first-page":"7302883","DOI":"10.1155\/2022\/7302883","article-title":"Research Progress based on regulation of tumor microenvironment redox and drug-loaded metal-organic frameworks","volume":"2022","author":"Xu","year":"2022","journal-title":"Oxidative Med Cell Longev"},{"issue":"12","key":"10.1016\/j.nano.2024.102743_bb0100","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41416-018-0287-3","article-title":"Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells","volume":"119","author":"Tian","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.nano.2024.102743_bb0105","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","article-title":"Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer","volume":"11","author":"Saatci","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.nano.2024.102743_bb0110","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.nano.2024.102743_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast Cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nano.2024.102743_bb0120","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jconrel.2021.01.033","article-title":"Hyaluronic acid and albumin based nanoparticles for drug delivery","volume":"331","author":"Lei","year":"2021","journal-title":"J Control Release"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963424000121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963424000121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T19:03:13Z","timestamp":1716663793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963424000121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"alternative-id":["S1549963424000121"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2024.102743","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioresponsive nanocomplex integrating cancer-associated fibroblast deactivation and immunogenic chemotherapy for rebuilding immune-excluded tumors","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2024.102743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102743"}}